Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2023-07-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于调整股票期权行权价格和限制性股票授予及回购价格的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from a company regarding adjustments to stock option exercise prices and restricted stock grant and repurchase prices. It includes extensive information about the approval procedures, board and supervisory meetings, independent director opinions, legal opinions, and the impact of these adjustments. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is also not a transcript, earnings release, or dividend notice. The content focuses on changes to stock-based compensation plans and related corporate governance approvals. This fits the category of a Regulatory Filing (RNS) because it is a regulatory announcement about corporate actions related to stock options and restricted stock, but it does not fit into more specific categories like Share Issue/Capital Change (SHA) or Remuneration Information (DEF 14A) since it is about price adjustments and approvals rather than initial compensation disclosures or new share issues. Therefore, the best classification is Regulatory Filings (RNS).
2023-07-28 Chinese
关于作废部分已授予尚未归属的第二类限制性股票的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the cancellation of certain unvested restricted stocks under its 2021 restricted stock incentive plan. It details board and supervisory meetings, legal opinions, and compliance with relevant laws and regulations. The content focuses on management decisions about stock incentives, including adjustments and cancellations, rather than financial results or earnings. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is not a proxy solicitation or voting result announcement. The document is a regulatory announcement about management decisions on stock incentives, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories like Remuneration Information or Share Issue/Capital Change, since it is about cancellation of granted but unvested restricted stock rather than new issuance or compensation details. The document length is over 5,000 characters and contains detailed information, so it is not a mere report publication announcement.
2023-07-28 Chinese
独立董事关于第五届董事会第六次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters discussed at the sixth meeting of the fifth board of directors of a company. It focuses on stock option cancellations, restricted stock cancellations, and adjustments to stock option exercise prices and restricted stock grant and repurchase prices. The content relates to corporate governance and board decisions regarding equity incentive plans. There is no indication that this is a full annual report, audit report, earnings release, or other financial report. It is not a simple announcement of voting results or a proxy solicitation. The document is a formal opinion from independent directors on board matters, which fits best under Board/Management Information (MANG). The document length is short (1406 characters), and it contains substantive content about board decisions, not just an announcement or certification. Therefore, the classification is MANG with high confidence.
2023-07-28 Chinese
第五届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the sixth meeting of the fifth board of directors of the company. It details the meeting attendance, the agenda items discussed, voting results, and references to related announcements published on a regulatory disclosure website. The content focuses on board decisions regarding stock option adjustments, cancellations, and related corporate governance matters. It does not contain financial statements or detailed financial performance data, nor is it a transcript or presentation. The document is an official announcement of board meeting resolutions, which fits the category of Board/Management Information (MANG). The document length is short (2038 characters), and it is not merely announcing the publication of a report but is itself the announcement of board decisions.
2023-07-28 Chinese
国浩律师（深圳）事务所关于健帆生物科技集团股份有限公司注销部分股票期权的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation of certain stock options of a company. It details the approval and authorization process, the reasons for cancellation, and the quantities involved. The document is not a financial report, earnings release, or regulatory filing about financial results. It is a legal opinion related to corporate governance and stock option plans, specifically about the cancellation of stock options. This type of document does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update. It is a specialized legal opinion letter concerning stock option cancellations, which is best classified under Regulatory Filings (RNS) as it does not fit other more specific categories and is a compliance/legal document.
2023-07-28 Chinese
国浩律师（深圳）事务所关于公司作废部分已授予尚未归属的第二类限制性股票的法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation of certain unvested restricted shares under a 2021 restricted stock incentive plan of a company. It details the legal basis, approvals, authorizations, and specific circumstances for the cancellation of these shares. The document is not a financial report, earnings release, or management discussion. It is a standalone legal opinion related to corporate governance and stock incentive plan compliance. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory filing or announcement of a report but a substantive legal opinion document. Therefore, the best fitting category is Audit Report / Information (AR), as it includes legal audit and compliance verification related to the stock incentive plan and its cancellation. FY 2022
2023-07-28 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.